Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease
Sponsor: Hoffmann-La Roche
Summary
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and established cardiovascular disease (CVD).
Official title: A Phase III, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide Vs. Placebo in Participants With Overweight Or Obesity And Established Cardiovascular Disease
Key Details
Gender
All
Age Range
40 Years - Any
Study Type
INTERVENTIONAL
Enrollment
2500
Start Date
2026-09-30
Completion Date
2030-10-06
Last Updated
2026-10-07
Healthy Volunteers
No
Interventions
Petrelintide
Petrelintide will be administered subcutaneously (SC) using a drug-device combination product.
Placebo
Petrelintide-matching placebo will be administered SC using a drug-device combination product.
Locations (3)
Pinnacle Research Group
Anniston, Alabama, United States
Institute for Metabolic Research Los Angeles
Los Angeles, California, United States
Progressive Medical Research
Port Orange, Florida, United States